Summit Therapeutics Inc 6-K, filed Apr 20, 2020
Summit Therapeutics Inc. (SMMT)
About this 6-K
Summit Therapeutics Inc filed this 6-K on April 20, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2020.
Commission File Number 001-36866
SUMMIT THERAPEUTICS PLC
(Translation of registrant’s name into English)
136a Eastern Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On April 13, 2020, the Board of Directors (the “Board”) of Summit Therapeutics plc (the “Company) appointed current director Dr. Elaine Stracker as interim Chief Operating Officer of the Company.
On April 17, 2020, the Board (i) appointed current director Dr. Ventzislav Stefanov as Executive Vice President of the Company and President of Discuva and (ii) elected Ramses Erdtmann to serve as a non-executive director of the Company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SUMMIT THERAPEUTICS PLC | ||||||
| Date: April 20, 2020 | By: | /s/ Robert Duggan | ||||
| Robert Duggan | ||||||
| Chief Executive Officer | ||||||